MEDICINE CABINET: TYPES OF TREATMENT Download and Print This Medication Sheet In recent years, many drugs have been FDA-approved to treat chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). It
In heavily treated chronic lymphocytic leukemia patients who have poor prognoses and few options, the BTK degrader, NX-5948, was responsive.
Rituximab can be given in combination with many other medications to treat CLL or SLL.
CLL Society awarded Dr. Jennifer Brown a research grant for her project testing the combination of venetoclax and obinutuzumab with roginolisib for CLL.
Venetoclax monotherapy is effective for treating relapsed / refractory CLL, including in patients previously treated with BTK or PI3K inhibitors.
Acalabrutinib has a low risk of sudden death and ventricular arrhythmias in chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL) patients.
Acalabrutinib and zanubrutinib have similar excellent efficacy in relapsed or refractory chronic lymphocytic leukemia (CLL).
Understanding the medication you are on, or those you and your healthcare provider are considering for your treatment plan is important in decision-making, managing expectations, and addressing concerns and side effects in order to maximize the benefits of therapy.
Follow-up results from a phase 1/2 trial of acalabrutinib in CLL / SLL patients further confirm that acalabrutinib is safe & effective.
